Locust Walk

We're Hiring! Locust Walk is looking for an Associate and an Experienced Analyst to join our #Boston team. If you're passionate about biotech and want to work on impactful projects with global clients in strategic transactions, private fundraising, and corporate strategy, this opportunity is for you! We are not your typical investment bank. Think of us as an investment bank, consulting firm, and corporate development team all wrapped into one specializing in biotech. Everyone on our deal team has a science background. The learning curve is much steeper, and the exposure is far more diverse than any one bank or consulting firm could offer. We are also starting new companies, and every team member gets involved in these ventures. Why Locust Walk? Join a dynamic team where success is a shared mission. We are entrepreneurial, growth-oriented, and constantly challenge convention. We believe in open, honest communication—both with our clients and within our team. Here, you'll gain hands-on experience, grow from within, and thrive in a collaborative environment. #EnjoytheRide with us! Associate application here: https://lnkd.in/eXbVHtFe Experienced Analyst application here: https://lnkd.in/e3NhCGgD  #NowHiring #CareerOpportunities #Biopharma #LifeScienceJobs #BostonJobs #Biotech #JoinUs

Great insights from MassBio’s Economic Outlook Forum! Our own Geoff Meyerson joined industry leaders to discuss macroeconomic trends, early-stage biotech challenges, and the evolving investment landscape. Encouraging to hear perspectives on innovation and growth in 2024—Geoff shared his increasing optimism for the year ahead. Thanks to MassBio for bringing the community together! #Biotech #MassBio #Innovation

The latest Biotalk episode dives into Asia’s 2024 Year-In-Review with Geoff Meyerson, Locust Walk’s CEO. Geoff explores key biotech trends in Japan and China, sharing insights from our 2024 Year-In-Review Report. “Looking ahead to 2025, we expect Chinese innovation to increasingly flow to the US via strategic transactions, capital markets, and NewCos, despite regulatory hurdles and potential geopolitical headwinds.” Key Highlights: 🔹 Cross-border partnerships driving innovation 🔹 Trends in venture financing and licensing deals 🔹 Strategic shifts shaping Asian biopharma Don’t miss Geoff’s take on how Asia’s growth is shaping global biotech. Listen now: https://lnkd.in/e_qYyvnN Download our 2024 Year-In-Review Market Conditions Report: https://lnkd.in/egFvFumW #Biotalk #Biotech #AsiaBiotech #VentureFunding #CrossBorderDeals

Capital market activity in 2024 increased by 156% and 93% compared to 2022 and 2023, respectively, driven by robust follow-on offerings and private financings. Despite a relative slowdown in late 2024, Q4 continued the trend of gradual recovery, reflecting strong investor appetite for established companies and validated growth opportunities. Learn more insights by downloading Locust Walk's 2024 Year-In-Review Market Conditions Report: https://lnkd.in/egFvFumW #Biopharma #CapitalMarkets #FollowOns #PrivateFinancing #LocustWalk

In the latest episode of Biotalk, Geoff Meyerson dives into our 2024 Year-In-Review Market Conditions Report. Geoff highlights, "Overall, we’re seeing positive momentum building in biotech, and we expect 2025 to outperform 2024, particularly in IPOs, public offerings, and especially in M&A and licensing, which we believe will be the key driver of growth." Listen to the full episode of Biotalk here: https://lnkd.in/ekiS39jT Download Locust Walk’s 2024 Year-In-Review Market Conditions Report: https://lnkd.in/egFvFumW Stay tuned for our upcoming podcast focused on Asian markets! #Biotech #MergersAndAcquisitions #Licensing #IPOs #Biopharma #MarketTrends #LifeSciences #VentureCapital #Biotalk

Aggregate licensing deal value by China-based companies climbed significantly in Q4 2024, increasing 87% QoQ, driven by early-stage deals in oncology, cardiovascular, and metabolic TAs. Discovery and preclinical assets dominated, reflecting pharma's focus on pipeline replenishment for the impending patent cliffs. Learn more insights by downloading Locust Walk's 2024 Year-In-Review Market Conditions Report: https://lnkd.in/egFvFumW #Biopharma #LicensingDeals #MarketTrends #LocustWalk 

Each quarter, Locust Walk's deal team compiles key statistics and trends on strategic transactions and financings. Our 2024 Year-In-Review Report applies the latest data to analyze the current landscape in life sciences deals. Biopharma saw steady Q4 recovery with a 70% surge in strategic deal value and resilient follow-on offerings despite a stalled IPO market. 2024’s flat XBI performance (-0.2%) contrasted sharply with the S&P 500’s 24 percentage points gain. Venture financing grew 59% YoY, driven by later-stage deals. 2025 recovery hinges on macroeconomic stability, regulatory clarity, and sustained investor confidence.    Click here to download the report: https://lnkd.in/egFvFumW   Next week, Locust Walk will release additional commentary on the present and future state of biopharma on our podcast, Biotalk.       #biopharma #markettrends #lifesciences #global #deals #financing #strategictransactions 

Congratulations to Errik Anderson and the entire Alloy Therapeutics, Inc. team! We’re grateful to have had the opportunity to play a role in helping Alloy Therapeutics, Inc. achieve their first announced transaction for the AntiClastic platform. Their collaboration and licensing deal with Sanofi, valued at $27.5M upfront and preclinical milestones, $400M in additional milestones, and royalties, is a testament to their hard work and innovation. #Biotech #Transactions #LicensingDeal #StrategicPartnerships 

As we kick off an exciting 2025, we would like to congratulate our Locust Walk team members who have earned well-deserved #promotions! Your commitment, hard work, and passion for delivering exceptional results to our clients and our team have truly made a significant impact.   Please join us in celebrating the achievements of Chris Andaloro, John Blythe, Saakshi Chadha, PhD, Jeffrey Desloge, Osvaldo Fernandez, Alex Hogenhuis, Sam Kessel MD, MBA, Chris Nyhan, and Sasha Tamarkin.   Locust Walk is hiring! If you’re ready to join a dynamic, growth-focused team, check out our current openings here: https://lnkd.in/d-_mg47   #EnjoyTheRide #LocustWalkLife #Congratulations #LifeScienceCareers #JoinOurTeam #LifeScienceJobs #CareerGrowth

Biotalk Wrapped: The Locust Walk team is incredibly grateful for the engaging and thought-provoking conversations featured on our Biotalk podcast series in 2024! From discussions on market conditions and the impact of U.S. elections on biotech, to exploring biopharma investment trends, the evolving role of AI in drug discovery, RNA therapeutics, and so much more, 2024 has been a year of insightful perspectives and dynamic dialogue. A special thank you to the inspiring industry leaders who joined us this year: Kendalle Burlin O'Connell, Esq. of MassBio, Stephen Sands of Lazard, Lindsay Rosenwald of Fortress Biotech, David H. of CytoReason, Sudhir Agrawal D.Phil, FRSC of ARNAY Sciences! If you haven’t tuned in yet, there’s time to catch up! We’re excited to continue these discussions in 2025 with more insights from the forefront of life sciences. 🎧 Spotify: https://lnkd.in/eQpkvSZy 🎧 Apple Podcasts: https://lnkd.in/emynu33f #BioTalk #Biotech #LifeSciences #Innovation #Podcast